Based on the key indicators related to Nanobac Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Nanobac Pharmaceuticals Incorporated may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Nanobac Pharmaceuticals' Other Current Liabilities is relatively stable compared to the past year. As of 02/01/2025, Intangible Assets is likely to grow to about 4.2 M, while Accounts Payable is likely to drop slightly above 616.8 K. Key indicators impacting Nanobac Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Nanobac Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Nanobac Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Nanobac Pharmaceuticals.
Nanobac Pharmaceuticals competes with Silo Pharma, NRx Pharmaceuticals, Aerovate Therapeutics, Molecular Partners, and MediciNova. Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles . The company was founded in 1994 and is based in Tampa, Florida. Nanobac Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Nanobac Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Nanobac Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nanobac Pharmaceuticals competition to find correlations between indicators driving Nanobac Pharmaceuticals's intrinsic value. More Info.
Nanobac Pharmaceuticals Incorporated is rated below average in return on asset category among its peers. It is rated below average in operating margin category among its peers . At this time, Nanobac Pharmaceuticals' Operating Profit Margin is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Nanobac Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Nanobac Pharmaceuticals Systematic Risk
Nanobac Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Nanobac Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Nanobac Pharmaceuticals correlated with the market. If Beta is less than 0 Nanobac Pharmaceuticals generally moves in the opposite direction as compared to the market. If Nanobac Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Nanobac Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Nanobac Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Nanobac Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Nanobac Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Nanobac has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Nanobac Pharmaceuticals' financials are consistent with your investment objective using the following steps:
Review Nanobac Pharmaceuticals' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand Nanobac Pharmaceuticals' liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare Nanobac Pharmaceuticals' financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Nanobac Pharmaceuticals' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in Nanobac Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Nanobac Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Nanobac Pharmaceuticals growth as a starting point in their analysis.
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.